The Filing Desk

Madrigal Pharmaceuticals

MDGL · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

MDGL · Last close · November 19, 2026
$396.74
Value Madrigal Pharmaceuticals yourself

Madrigal Pharmaceuticals' revenue rose 432.1% to $958 million in fiscal 2025. Its operating margin was −31.3%, up from −276.4% a year earlier. Free cash flow was −$190 million. The diluted share count rose 5.5%.

MADRIGAL PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001628280-26-009514 Updated
Revenue
$958M
432.1%
Operating margin
−31.3%
245.1 pts
Net income
−$288M
 
Free cash flow
−$190M
 
Return on equity
−42.5%
37.9 pts
Market cap
$12.0B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Gross margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Madrigal Pharmaceuticals lost money in fiscal 2025: a net loss of $288 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments270359634931984
Debt incl. finance leases070116118340
Net debt (negative means net cash)−270−289−519−814−644
Net debt to EBITDA—————
Debt to equity0.0x0.3x0.3x0.2x0.6x
Interest coverage—−74.1x−29.9x−33.9x−13.4x
Current ratio3.5x3.1x5.4x6.1x4.0x
Quick ratio3.5x3.1x5.4x5.9x3.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Madrigal Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Madrigal Pharmaceuticals shares on the open market, and 8 insiders sold $69.0 million, $61.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 11, 2026William John SiboldPresident and CEO, DirectorSold plan5,221$542.38$2.8 millionForm 4
Sep 9, 2026William John SiboldPresident and CEO, DirectorSold plan6,362$535.59$3.4 millionForm 4
Aug 17, 2026Shannon T KelleyGeneral CounselSold664$514.97$341,940Form 4
Jul 20, 2026William John SiboldPresident and CEO, DirectorSold2,500$547.30$1.4 millionForm 4
Jun 1, 2026David SoergelChief Medical OfficerSold plan1,042$495.74$516,561Form 4
May 22, 2026Richard S LevyDirectorSold plan5,682$515.44$2.9 millionForm 4
May 18, 2026David SoergelChief Medical OfficerSold844$515.90$435,420Form 4
Mar 6, 2026Mardi DierEVP and CFOSold plan1,982$430.87$853,993Form 4
Mar 6, 2026William John SiboldPresident and CEO, DirectorSold1,663$431.94$718,316Form 4
Mar 6, 2026Rebecca TaubDirectorSold491$431.94$212,083Form 4
Mar 6, 2026Carole HuntsmanChief Commercial OfficerSold419$431.94$180,983Form 4
Mar 6, 2026Shannon T KelleyGeneral CounselSold360$431.94$155,498Form 4
The latest 12 of 27 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 85 of 83 of 8
Rule of 40——412.2%
Altman Z''−3.67−0.66−1.18
Accruals ratio−9.8%−1.2%−8.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score3 of 85 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Madrigal Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Madrigal PharmaceuticalsFY25432.1%−31.3%−19.8%——3
Ionis PharmaceuticalsFY2533.8%−40.5%−33.9%——3Compare
Tilray BrandsFY2611.5%−6.9%—−3.4%—3Compare
ANI PharmaceuticalsFY2543.8%12.6%19.4%15.9%0.1x6Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—0000000180958
Revenue growth—————————432.1%
Gross profit——————00174—
Research and development16242572185205245272237388
Operating income−25−32−41−95−207−242−294−380−498−300
Net income−26−31−33−84−202−242−295−374−466−288
Diluted EPS (US$)−5.07−2.54−2.22−5.45−13.09−14.63−17.23−19.99−21.90−12.85
Diluted shares (millions)5121515151617192122
Cash flow
Cash from operations−18−22−26−42−158−184−225−324−456−190
Capital expenditure0000000220
Free cash flow−18−22−26−42−158−184−225−326−457−190
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation831423212732508098
Balance sheet at fiscal year end
Cash and short-term investments19192484439284270359634931984
Debt incl. finance leases—————070116118340
Total assets411924854422872733636401,0421,260
Total liabilities5108264777165235288657
Shareholders' equity36182477417240196197405754603
Margins and ratios
Gross margin————————96.5%—
Operating margin————————−276.4%−31.3%
Net margin————————−258.6%−30.1%
Free cash flow margin————————−253.7%−19.8%
Rule of 40 (growth + FCF margin)—————————412.2%
Return on capital——————————
Return on equity—−28.5%−9.9%−18.8%−61.6%−110.9%−150.1%−124.0%−80.3%−42.5%
Return on assets−127.0%−26.7%−9.7%−18.1%−55.5%−86.3%−92.9%−74.5%−55.4%−25.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Madrigal Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Madrigal Pharmaceuticals.